# Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies

Source: https://onco.cc/trials/nct06801002/  
OnCo record `nct06801002` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of JBZ-001 run by Jabez Bioscience, Inc, now recruiting.

## Summary

Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies is a phase 1 interventional study registered as NCT06801002 by Jabez Bioscience, Inc, with 25 participants planned, started 2025-03-17. Conditions recorded: Solid Tumor. Interventions recorded: JBZ-001.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06801002
- Phase: 1
- Setting: A Phase 1, Open-label, Dose-escalation and Expansion, First-in-human Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JBZ-001, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Patients With Advanced Solid and Hematological Malignancies
- Sponsor: Jabez Bioscience, Inc
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT06801002: https://clinicaltrials.gov/study/NCT06801002

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [JBZ-001](https://onco.cc/drugs/jbz-001/)
- companies: [Jabez Biosciences](https://onco.cc/companies/jabez-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct06801002.json